Company intelligence / Profile preview

Dr. Max

Prague, Czech Republicdrmax.eu ↗

Ownership: Private
Employees: ~20000
Development stage: Commercial

Overview

Dr. Max is the second largest pharmacy chain in Europe and a leading pharmaceutical manufacturer in Central and Eastern Europe with over 3,000 pharmacies across 17 countries. Its subsidiary, Dr. Max Pharma s.r.o., develops private label pharmaceuticals and medical products for its retail network and has shown rapid growth—reporting a 34% revenue increase in 2023 with nearly 300 drug registrations and around 1,300 SKUs for medicines/non-medicines[5]. The company focuses on affordability and accessibility of healthcare products.

Therapeutic areas: Other
Modalities: Small moleculeBiologicMedical deviceFood supplement
Industry: Non-Academic Healthcare

Partnerships

Collaborations with global suppliers for product development/manufacturing; no major pharma/biotech partnerships disclosed.

Beyond the preview

Go deeper on Dr. Max.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr. Max.

Explore the full profile